ZYBT Stock Analysis: Buy, Sell, or Hold?
ZYBT - Zhengye Biotechnology Holding Limited Ordinary Shares
$0.95
-0.01 (-0.98%)
▼
5d:
-2.83%
30d:
-14.42%
90d:
-5.95%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Get Alerted When ZYBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZYBT shows positive signals but monitor for confirmation. Moderate conviction.
💡 BUY OPPORTUNITY: ZYBT shows positive signals but monitor for confirmation. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ZYBT is currently trading at $0.95, which is considered fair relative to its 30-day fair value range of $0.89 to $1.05.
Technical Outlook: Technically, ZYBT is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.30.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZYBT is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.30.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.89 -
$1.05
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.8%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
Trading Range Analysis
30-Day Trading Range
$0.89 -
$1.05
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.30
Current Trend
Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Revenue Growth (YoY)
-40.9%
Earnings Growth (YoY)
-79.6%
Profit Margin
-60.0%
Share & Embed Analysis
Last updated: May 15, 2026 8:36 AM ET
Data refreshes hourly during market hours. Next update: 9:36 AM
Data refreshes hourly during market hours. Next update: 9:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYBT showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
